Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles

American Journal of Transplantation

Volumn 16, Issue 2, 2016, Pages 574-582

  Oetting, William S ^a   Schladt, D P ^b   Guan, W ^a   Miller, M B ^a   Remmel, R P ^a   Dorr, C ^b   Sanghavi, K ^a   Mannon, R B ^c   Herrera, B ^d   Matas, A J ^e   Salomon, D R ^f   Kwok, P Y ^d   Keating, B J ^g   Israni, A K ^a,b,e   Jacobson, P A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

basic (laboratory) research science; genetics; genomics; immunosuppressant; calcineurin inhibitor: tacrolimus; immunosuppression immune modulation; microarray gene array; molecular biology: DNA; molecular biology: single polynucleotide polymorphism

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; BASILIXIMAB; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 3A4P2; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG USE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; ADVERSE EFFECTS; CAUCASIAN; CHILD; DONOR; ETHNOLOGY; FOLLOW UP; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GRAFT REJECTION; GRAFT SURVIVAL; INFANT; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MIDDLE AGED; NEWBORN; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; PROGNOSIS; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ALLELES; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS; TACROLIMUS; TISSUE DONORS; TRANSPLANT RECIPIENTS; YOUNG ADULT;

EID: 84957955419     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13495     Document Type: Article

References (27)

1. Iwasaki, K, Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 2007; 22: 328-335.
2. Dai Y, Hebert MF, Isoherrannen N, et al., Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34: 836-847.
3. Jacobson PA, Oetting WS, Brearley AM, et al., Novel polymorphisms associated with tacrolimus trough concentrations: Results from a multicenter kidney transplant consortium. Transplantation 2011; 91: 300-308.
4. Bruckmueller H, Werk AN, Renders L, et al., Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus. Ther Drug Monit 2015, 37: 288-295.
5. Rojas L, Neumann I, Herrero MJ, et al., Effect of CYP3A5 3 on kidney transplant recipients treated with tacrolimus: A systematic review and meta-analysis of observational studies. Pharmacogenomics J 2015; 15: 38-48.
6. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA., Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol 2011; 72: 948-957.
7. Passey C, Birnbaum AK, Brundage RC, et al., Validation of tacrolimus equation to predict troughs using genetic and clinical factors. Pharmacogenomics 2012; 13: 1141-1147.
8. Neylan JF., Immunosuppressive therapy in high-risk transplant patients: Dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1997; 64: 1277-1282.
9. Laftavi MR, Pankewycz O, Patel S, et al., African American renal transplant recipients (RTR) require higher tacrolimus doses to achieve target levels compared to white RTR: Does clotrimazole help ? Transplant Proc 2013; 45: 3498-3501.
10. Gralla J, Le CN, Cooper JE, Wiseman AC., The risk of acute rejection and the influence of induction agents in lower-risk African American kidney transplant recipients receiving modern immunosuppression. Clin Transplant 2014; 28: 292-298.
11. Neylan JF., Effect of race and immunosuppression in renal transplantation: Three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. Transplant Proc 1998; 30: 1355-1358.
12. Taber DJ, Gebregziabher MG, Srinivas TR, Chavin KD, Baliga PK, Egede LE., African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients. Pharmacotherapy 2015, 35: 569-577.
13. Israni A, Leduc R, Holmes J, et al., Single-nucleotide polymorphisms, acute rejection, and severity of tubulitis in kidney transplantation, accounting for center-to-center variation. Transplantation 2010; 90: 1401-1408.
14. Hoffmann TJ, Kvale MN, Hesselson SE, et al., Next generation genome-wide association tool: Design and coverage of a high-throughput European-optimized SNP array. Genomics 2011; 98: 79-89.
15. Vignettes: Genotype clustering for Axiom™ arrays. Affymetrix Web site. [updated 2009 Oct 12]. Available from: http://media.affymetrix.com/support/technical/whitepapers/brlmmp-whitepaper.pdf
16. Li YR, van Setten J, Verma SS, et al., Concept and design of a genome-wide association genotyping array tailored for transplantation-specific studies. Genome Med 2015; 7: DOI 10.1186/s13073-015-0211-x.
17. Purcell S, Neale B, Todd-Brown K, et al., PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
18. Jacobson PA, Schladt D, Oetting WS, et al., Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant 2012; 12: 3326-3336.
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D., A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130: 461-470.
20. Hustert E, Haberl M, Burk O, et al., The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-779.
21. Kuehl P, Zhang J, Lin Y, et al., Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
22. Narayanan M, Pankewycz O, Shihab F, Wiland A, McCague K, Chan L., Long-term outcomes in African American kidney transplant recipients under contemporary immunosuppression: A four-yr analysis of the Mycophenolic acid Observational REnal transplant (MORE) study. Clin Transplant 2014; 28: 184-191.
23. Hustert E, Haberl M, Burk O, et al., The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-779.
24. Pallet N, Jannot AS, El Bahri M, et al., Kidney transplant recipients carrying the CYP3A422 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. Am J Transplant 2015; 15: 800-805.
25. Kurzawski M, Dąbrowska J, Dziewanowski K, Domański L, Perużyńska M, Droździk M. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. Pharmacogenomics 2014, 15: 179-188.
26. Bains RK, Kovacevic M, Plaster CA, et al., Molecular diversity and population structure at the cytochrome P450 3A5 gene in Africa. BMC Genet 2013; 14: 34.
27. 1000 Genomes. Available from: http://browser.1000genomes.org/Homo-sapiens/Gene/Variation-Gene/Table?db=core;g=ENSG00000106258;r=7:99245817-99277621